2020
Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII study
2010
An Updated Report on the Pathologic Complete Response and Survival Outcome of Southwest Oncology Group (SWOG S0536): A Phase II Trial of Oxaliplatin (oxp) Plus Protracted Infusion 5-Fluorouracil (PIFU) and External Beam Radiation (EBRT) Prior to Surgery(s) for Potentially Curable Esophageal Adenocarcinoma (EA) with Molecular Correlates
Leichman L, Goldman B, Thomas C, Billingsley K, Corless C, Lenz H, Iqbal S, Benedetti J, Gold P, Blanke C. An Updated Report on the Pathologic Complete Response and Survival Outcome of Southwest Oncology Group (SWOG S0536): A Phase II Trial of Oxaliplatin (oxp) Plus Protracted Infusion 5-Fluorouracil (PIFU) and External Beam Radiation (EBRT) Prior to Surgery(s) for Potentially Curable Esophageal Adenocarcinoma (EA) with Molecular Correlates. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s28-s29. DOI: 10.1016/j.ijrobp.2010.07.106.Peer-Reviewed Original Research
2009
Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)
Leichman L, Goldman B, Benedetti J, Billingsley K, Thomas C, Iqbal S, Lenz H, Blanke C, Gold P, Corless C. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). Journal Of Clinical Oncology 2009, 27: 4513-4513. DOI: 10.1200/jco.2009.27.15_suppl.4513.Peer-Reviewed Original ResearchExternal beam radiationPathologic complete responsePhase II trialOverall survivalEsophageal adenocarcinomaII trialSouthwest Oncology Group phase II trialGrade 3/4 toxicitiesMedian overall survivalNon-hematologic toxicitiesCentral pathology reviewPrimary tumor responseCooperative group trialsStandard of careTumor molecular profilesAcceptable toxicityFree survivalModality therapyComplete responseGastric cardiaNew regimensPathology reviewFuture trialsTumor responseSitu cancer
2006
Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study
Whitehead R, McCoy S, Wollner I, Wong L, Harker W, Hoff P, Gold P, Billingsley K, Blanke C. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. Journal Of Clinical Oncology 2006, 24: 3598-3598. DOI: 10.1200/jco.2006.24.18_suppl.3598.Peer-Reviewed Original ResearchPrior chemotherapy regimensAdvanced colorectal cancerPhase II trialColorectal cancerEligible patientsChemotherapy regimensII trialPerformance statusSouthwest Oncology Group studyCommon grade 2Prior chemotherapy regimenZubrod performance statusMetastatic colorectal cancerMonths overall survivalColorectal cancer patientsSerum magnesium levelsSignificant anti-tumor activityKaplan-Meier estimatesAdditional active agentsAnti-tumor activityHistone deacetylase inhibitorsMurine model systemBaseline labsMeasurable diseasePrior regimens